Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist-Reference-Cited by-同舟云学术

Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist

Published:2021-07-19 Issue:15 Volume:64 Page:11554-11569
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Xi-Feng¹,Zhang Meng-Jia²,He Na¹,Wang Ya-Cong¹,Yan Cheng¹,Chen Xiang-Zhao³,Gao Xiao-Fei⁴,Guo Jun¹^ORCID,Luo Rui²,Liu Zheng¹^ORCID

Affiliation:

1. Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, Hubei International Scientific and Technological Cooperation Base of Pesticide and Green Synthesis, International Joint Research Center for Intelligent Biosensing Technology and Health, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, P. R. China

2. State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei 430070, P. R. China

3. Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou, Jiangxi 341000, China

4. Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, East China University of Technology, Nanchang, Jiangxi 330013, China

Funder

Ministry of Education of the People's Republic of China

Wuhan Municipal Science and Technology Bureau

National Natural Science Foundation of China

Higher Education Discipline Innovation Project

Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link